Mark Owen
Hematology & Oncology · Cleveland, TNNPI 1811761588
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,201, more than ten times the $62 reported in 2023. That places this record below the midpoint for hematology & oncology clinicians in TN, where the typical reported total is $5,575.
Across 104 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$330
- Daiichi Sankyo Inc.$290
- Incyte Corporation$204
- AstraZeneca$148
- Bristol Myers Squibb$123
- GSK$108
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,35296%
- Education$884%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 20 | $330 |
| Daiichi Sankyo Inc. | 11 | $290 |
| Incyte Corporation | 6 | $204 |
| AstraZeneca(2 entities) | 6 | $148 |
| Bristol Myers Squibb | 5 | $123 |
| GSK | 5 | $108 |
| Pfizer | 5 | $105 |
| Bayer | 3 | $104 |
| Regeneron Healthcare Solutions, Inc. | 3 | $92 |
| Exelixis Inc. | 2 | $76 |
| Tersera Therapeutics LLC | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $70 |
| Johnson & Johnson | 3 | $55 |
| Sanofi | 2 | $53 |
| Astellas Pharma US Inc | 2 | $52 |
| Sun Pharmaceutical Industries Inc. | 2 | $47 |
| Merck | 2 | $43 |
| Gilead | 2 | $43 |
| Lilly USA, LLC | 2 | $39 |
| Dendreon Pharmaceuticals LLC | 1 | $35 |
| Pharmacosmos Therapeutics Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $33 |
| Eisai Inc. | 1 | $30 |
| Medline Industries LP | 1 | $28 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| Geron Corporation | 1 | $22 |
| EMD Serono, Inc. | 1 | $21 |
| Genmab U.S., Inc. | 1 | $20 |
| Sobi, Inc | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| AbbVie | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
How this compares
$2,440 in reported general payments places this provider in the 30th percentile of 251 hematology & oncology providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,075 |
| Prochlorperazine Maleate | 13 | $296 |
| Ondansetron OdtOndansetron | 16 | $197 |
| Duloxetine Hcl | 12 | $168 |
| Gabapentin | 11 | $57 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Cleveland
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Jason PorterGermantown$756K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.